ABEO

Abeona Therapeutics Inc.

Healthcare
Biotechnology
$309M market cap

Forecast run · Sep 14, 2026Upside rank 1066 of 3,136

Model Signal

ForecastQ Daily Probabilities

43.7%

24.2%

21.9%

Analyst Consensus

Recommendation2.33/5 Buy

Last price$5.42

Price target$17.67

Implied move+226.3%

Analysts9

ForecastQ Portfolios

ABEO is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

Abeona Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, focused on creating innovative gene and cell therapies to address severe and uncommon genetic diseases. Its leading program, EB-101, an autologous gene-corrected cell therapy, is presently in a Phase III clinical trial for treating recessive dystrophic epidermolysis bullosa. The company's pipeline also features several other promising therapies: ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A. ABO-201, intended for CLN3 disease. ABO-401, developed to treat cystic fibrosis. ABO-50X, aimed at various genetic eye disorders. Additionally, Abeona is advancing AAV-based gene therapy solutions through its proprietary AIM vector platform. The company, which was founded in 1974 and is headquartered in New York, New York, changed its name to Abeona Therapeutics Inc. in June 2015, having previously been known as PlasmaTech Biopharmaceuticals, Inc.